- Original research
- Open Access
Isolated vertebral fractures give elevated serum protein S-100B levels
Scandinavian Journal of Trauma, Resuscitation and Emergency Medicinevolume 16, Article number: 13 (2008)
Serum protein S-100B determinations have been widely proposed in the past as markers of traumatic brain injury and used as a predictor of injury severity and outcome. The purpose of this prospective observational case series was therefore to determine S-100B serum levels in patients with isolated injuries to the back.
Between 1 February and 1 May 2008, serum samples for S-100B analysis were obtained within 1 hour of injury from 285 trauma patients. All patients with a head injury, polytrauma, and intoxicated patients were excluded to select isolated injuries to the spine. 19 patients with isolated injury of the back were included. Serum samples for S-100B analysis and CT spine were obtained within 1 hours of injury.
CT scans showed vertebral fractures in 12 of the 19 patients (63%). All patients with fractures had elevated S-100B levels. Amongst the remaining 7 patients without a fracture, only one patient with a severe spinal contusion had an S-100B concentration above the reference limit. The mean S-100B value of the group with fractures was more than 4 times higher than in the group without fractures (0.385 vs 0.087 μg/L, p = 0.0097).
Our data, although limited due to a very small sample size, suggest that S-100B serum levels might be useful for the diagnosis of acute vertebral body and spinal cord injury with a high negative predictive power. According to the literature, the highest levels of serum S-100B are found when large bones are fractured. If a large prospective study confirms our findings, determining the S-100B level may contribute to more selective use of CT and MRI in spinal trauma.
The reliable detection of spinal injury remains difficult despite major progress in imaging techniques. Computed tomography and now MRI are recommended as the gold standard for the early detection of spinal injuries. The indication for computed tomography in spinal trauma patients is still controversial, as not all hospitals have 24-hour access to such modalities and transfers are cost-intensive and may be linked to increased morbidity and mortality. Serum protein S-100B determinations have been widely proposed in the past as markers of traumatic brain injury and used as a predictor of injury severity and outcome. [1–4] S-100 protein is a low molecular weight protein found in vertebrates characterized by two calcium binding sites of the helix-loop-helix ("EF-hand type") conformation. There are at least 21 different types of S-100 protein. The name is derived from the fact that the protein is 100% soluble in ammonium sulfate at neutral pH. S-100 is normally present in cells derived from the neural crest (Schwann cells, melanocytes, and glial cells), chondrocytes, adipocytes, myoepithelial cells, macrophages, Langerhans cells, dendritic cells, and keratinocytes. S-100 proteins have been implicated in a variety of intracellular and extracellular functions. S100 proteins are involved in regulation of protein phosphorylation, transcription factors, Ca++ homeostasis, the dynamics of cytoskeleton constituents, enzyme activities, cell growth and differentiation, and the inflammatory response. Recent studies suggested that S-100B protein may be a biomarker for traumatic spinal cord injury in an animal model . In trauma patients, S-100B shows a high negative predictive power for head injuries, but is also elevated in larger extracranial injuries, especially in fractures. [7, 8] However, little is known about the effects of isolated vertebral injuries on S-100B serum concentrations.
The purpose of this prospective observational case series was therefore to determine the levels of S-100B serum levels in patients with isolated injuries to the spine. Our aim was to determine whether S-100 B is a reliable serum marker for spinal injuries and, if so, whether it is reliable in spinal injury both with and without fractures of the spinal column.
Our site is a Swiss level-one emergency unit with a 24-hour trauma service, seeing about 500 severely injured (ISS > 16) patients per year.
Between 1 February and 1 May 2008, serum samples for S-100B analysis were obtained within 1 hour of injury from285 trauma patients. All patients with a head injury, GCS < 15, polytrauma, patients with limb or torso injuries, intoxicated or sedated patients, and patients with an unreliable history were excluded to select isolated injuries to the spine. 19 patients with isolated injuries to the spine remained for further analysis. The samples were assessed using a S-100 ECLIA (electrochemiluminescence immunoassay) method on a Modular Analytics E170 automated analyser (Roche Diagnostics AG, Rotkreuz, Switzerland). S-100B serum were designated as positive if concentrations were higher than 0.10 μg/L, the upper 95% reference limit for a normal healthy population. 
CT scans of the head and the complete spine from all patients were obtained using a 16-row detector CT scanner (Sensation16, Siemens, Erlangen, Germany) with a collimation between 0.75 and 1.5 mm. The scans were evaluated for traumatic lesions independently by a neuroradiologist and a spine surgeon who were blinded to the results of the S-100B measures.
CT scans showed vertebral fractures in 12 of the 19 patients (63%). All patients with fractures had elevated S-100B levels. Amongst the remaining 7 patients without a fracture, only one patient with a severe spinal contusion had an S-100B concentration above the reference limit. 4 of the 19 patients showed neurological symptoms; all these patients has clearly elevated S100B concentrations and all but the above mentioned patient with a spinal contusion had instable fractures (Table 1). The mean S-100B value in the group with fractures was more than 4 times higher than in the group without fractures (0.385 vs 0.087 μg/l, p = 0.0097). No correlation was found between age, gender or location of the fracture. Overall it seems that fractures of larger vertebrae and more complex fractures result in higher S-100B values. (Table 1)
S100B has a high positive and negative predictive power, and the finding of a normal S100B value shortly after trauma may exclude significant injury. Our data, although limited due to a very small sample size, suggest that S-100B serum levels might be a useful tool for the diagnosis of acute vertebral body and spinal cord injury. According to the literature, the highest levels of serum S-100B are found when large bones are fractured . The clear correlation between the vertebral fractures and elevated S-100B serum concentrations and the tendency to higher values with more complex fractures of larger bones make the bone marrow a more likely source of S-100B in serum than potentially injured nerve tissue. However, spinal cord injuries without fractures can also apparently elevate S-100B serum concentrations, although our sample was too small for reliable conclusions or statistics. If a large prospective study confirms our findings, determining the S-100B level may contribute to more selective use of CT and MRI in spinal trauma. It should be borne in mind that positive S-100B results may be over interpreted as a reliable positive predictor for injuries to the spine, especially if further injuries are present. In our sample, however, normal S-100B concentration were not found in the presence of relevant injuries. A limitation of our study is that axonal injuries cannot be excluded, even in patients without history of percussive trauma to the head. Such patients may show elevated S-100B levels as may patients with large soft-tissue injuries, although our aim was to exclude such cases we tried to exclude such as far as possible [1, 7].
The clinical impact of our positive S-100B findings is limited. It can, however, be assumed that patients with reduced consciousness (intoxicated, intubated, sedated) and a negative S-100B have no significant brain or spinal injury. This might contribute to sparing patients from unnecessary exposure to radiation, saving resources and ultimately reducing costs. Although our results are promising, no firm conclusions can be drawn at present. Future efforts to develop biomarkers that predict functional outcomes in the acute phase of spinal injury should also focus on axon-specific proteins.
Korfias S, Stranjalis G, Boviatsis E, Psachoulia C, Jullien G, Gregson B, Mendelow AD, Sakas DE: Serum S-100B protein monitoring in patients with severe traumatic brain injury. Intensive Care Med. 2007, 33 (2): 255-60. 10.1007/s00134-006-0463-4. Epub 2006
Dimopoulou I, Korfias S, Dafni U, Anthi A, Psachoulia C, Jullien G, Sakas DE, Roussos C: Protein S-100b serum levels in trauma-induced brain death. Neurology. 60 (6): 947-51. 2003 Mar 25
Dimopoulou I, Korfias S, Dafni U, Anthi A, Psachoulia C, Jullien G, Sakas DE, Roussos C, Raabe A, Kopetsch O, Woszczyk A, Lang J, Gerlach R, Zimmermann M, Seifert V: Serum S-100B protein as a molecular marker in severe traumatic brain injury. Restor Neurol Neurosci. 2003, 21 (3–4): 159-69. Review
Nylén K, Ost M, Csajbok LZ, Nilsson I, Hall C, Blennow K, Nellgård B, Rosengren L: Serum levels of S100B, S100A1B and S100BB are all related to outcome after severe traumatic brain injury. Acta Neurochir (Wien). 2008, 150 (3): 221-7. 10.1007/s00701-007-1489-2. discussion 227. Epub 2008 Jan
Donato R: "Intracellular and extracellular roles of S100 proteins". Microsc Res Tech. 2003, 60 (6): 540-51. 10.1002/jemt.10296.
Loy DN, Sroufe AE, Pelt JL, Burke DA, Cao QL, Talbott JF, Whittemore SR: Serum biomarkers for experimental acute spinal cord injury: rapid elevation of neuron-specific enolase and S-100beta. Neurosurgery. 2005, 56 (2): 391-7. 10.1227/01.NEU.0000148906.83616.D2. discussion 391–7
Savola O, Pyhtinen J, Leino TK, Siitonen S, Niemelä O, Hillbom M: Effects of head and extracranial injuries on serum protein S100B levels in trauma patients. J Trauma. 2004, 56 (6): 1229-34. discussion 1234
Pickering A, Carter J, Hanning I, Townend W: Emergency department measurement of urinary S100B in children following head injury: can extracranial injury confound findings?. Emerg Med J. 2008, 25 (2): 88-9. 10.1136/emj.2007.046631.
Cao F, Yang XF, Liu WG, Hu WW, Li G, Zheng XJ, Shen F, Zhao XQ, Lv ST: Elevation of neuron-specific enolase and S-100beta protein level in experimental acute spinal cord injury. J Clin Neurosci. 2008, 15 (5): 541-4. 10.1016/j.jocn.2007.05.014. Epub 2008 Mar 14
Alistair Reeves for critical reviewing and language corrections.
The authors declare that they have no competing interests.
LMB was responsible for data analysis and writing of the manuscript. CL and LM were collecting data. RK conducted all biochemical assessments. HZ performed the statistical analysis. AKE was responsible for study design and writing of the manuscript. All authors read and approved the final manuscript.
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.